Literature DB >> 8675249

Comparison of nifedipine alone and with diltiazem or verapamil in hypertension.

J J Saseen1, B L Carter, T E Brown, W J Elliott, H R Black.   

Abstract

Receptor binding studies suggest that combinations of calcium channel blockers may result in either enhanced or diminished pharmacological effects, but clinical data in hypertension are incomplete. In this study, we compared blood pressure reductions using nifedipine alone, nifedipine plus diltiazem, and nifedipine plus verapamil and determined whether combinations alter nifedipine pharmacokinetics. After determination of baseline blood pressures. 16 subjects with essential hypertension (12 men, 4 women; mean age, 48 years) received 30 mg/d open-label, sustained release nifedipine for 2 weeks. If still hypertensive (n = 16), they were randomized (double-blind) to receive either additional sustained release diltiazem or sustained release verapamil, both 180 mg/d, for 2 weeks and were then crossed-over for the final 2 weeks of the study. All medications were once-daily, extended-release formulations. Blood pressures and nifedipine plasma concentrations were measured during the final day of each treatment. Overall, each combination lowered mean systolic and diastolic pressures more than nifedipine alone. Mean supine diastolic pressures were significantly lower at 8 hours (77.6 versus 84.6 mm Hg, P = .001) and 12 hours (81.5 versus 87.1 mm Hg, P = .04) with nifedipine plus diltiazem than nifedipine plus verapamil. Mean nifedipine concentrations were inversely correlated with mean blood pressures. Mean nifedipine area under the curve values were greater with diltiazem than verapamil (1430 versus 1134 ng.h/mL, P = .026), with each greater than nifedipine alone (957 ng.h/mL). Nifedipine plus diltiazem had a greater antihypertensive effect than nifedipine plus verapamil. Diltiazem caused greater increases in nifedipine plasma concentrations than did verapamil. These data suggest that combined calcium channel blockers result in additive antihypertensive effects, perhaps because of a pharmacokinetic interaction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8675249     DOI: 10.1161/01.hyp.28.1.109

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  12 in total

Review 1.  Is fixed combination therapy appropriate for initial hypertension treatment?

Authors:  William J Elliott
Journal:  Curr Hypertens Rep       Date:  2002-08       Impact factor: 5.369

Review 2.  Non-interventional management of resistant hypertension.

Authors:  Michael Doumas; Costas Tsioufis; Charles Faselis; Antonios Lazaridis; Haris Grassos; Vasilios Papademetriou
Journal:  World J Cardiol       Date:  2014-10-26

Review 3.  Resistant Hypertension: Mechanisms and Treatment.

Authors:  Andrew Y Hwang; Eric Dietrich; Carl J Pepine; Steven M Smith
Journal:  Curr Hypertens Rep       Date:  2017-07       Impact factor: 5.369

Review 4.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

5.  Case studies in hypertension. Dihydropyridine/nondihydropyridine calcium channel blocker combination therapy.

Authors:  Joe Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-01       Impact factor: 3.738

Review 6.  Current concepts of pharmacotherapy in hypertension: combination calcium channel blocker therapy in the treatment of hypertension.

Authors:  D A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Sep-Oct       Impact factor: 3.738

Review 7.  Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension.

Authors:  David A Calhoun
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-01       Impact factor: 3.738

8.  Fixed-dosed combinations are not indicated as initial therapy: a debate.

Authors:  Barry L Carter
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-02       Impact factor: 3.738

9.  Current perspectives on combination therapy in the management of hypertension.

Authors:  Samir G Mallat; Houssam S Itani; Bassem Y Tanios
Journal:  Integr Blood Press Control       Date:  2013-06-17

10.  ASH position paper: treatment of hypertension in patients with diabetes-an update.

Authors:  George L Bakris; James R Sowers
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-09       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.